SNMMI Launches Thyroid Cancer Registry

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced the pilot launch of the Thyroid Cancer Registry, the newest addition to its Radiopharmaceutical Therapy Registry (RaPTR) platform. The Thyroid Cancer Registry joins existing registries focused on¹⁷⁷Lu-DOTATATE and¹⁷⁷Lu-PSMA-617, demonstrating SNMMI’s commitment to advancing nuclear medicine and molecular imaging through comprehensive data collection and analysis.

RaPTR aims to provide a robust infrastructure for capturing real-world evidence related to the safety, effectiveness, and clinical use of radiopharmaceutical therapies. By expanding RaPTR to include thyroid cancer, SNMMI seeks to support research and optimize patient outcomes for a wider spectrum of cancers treated with radiopharmaceutical therapies.

“The thyroid cancer registry, and RaPTR as a whole, represents a rich resource for clinical investigation and educational opportunities,” said Orhan K Oz, MD, PhD, professor at the University of Texas Southwestern and chair-elect of the RaPTR Registry Oversight Committee. “It will inform future clinical practice and prepare future leaders in the field, benefiting the medical and scientific communities of nuclear medicine and beyond.”

The pilot phase for the Thyroid Cancer Registry marks a significant milestone in SNMMI’s broader initiative to refine and expand its registry program. During this phase, SNMMI will collaborate with pilot centers across the country to evaluate the registry’s functionality, streamline data collection processes, and ensure its alignment with clinical needs. The society is actively recruiting additional pilot sites to participate in this critical phase and contribute to the program’s success.

“On behalf of the RaPTR committee and all SNMMI staff who have helped make this possible, we are thrilled to launch the new radioactive iodine therapy module,” said Rustain Morgan, MD, nuclear radiologist at the University of Nebraska and chair of the RaPTR Registry Oversight Committee. “We are confident that the creation of a national thyroid therapy registry will improve both patient care and outcomes.”

SNMMI anticipates completing the pilot phase for all three RaPTR registries in 2025, with plans to transition to a full launch before the year’s end. This comprehensive rollout will position RaPTR as an important resource for quality and patient safety in radiopharmaceutical therapy.